News & Insights
Stay Informed With Our Latest Updates
Explore our comprehensive collection of news and in-depth insights spanning practice areas, industries, and regions.
Firm News January 12, 2026
Gibson Dunn Represented Arrowhead Pharmaceuticals on Concurrent Public Offerings of Convertible Notes, Common Stock, and Pre-Funded Warrants and Related Capped Call Transactions
Gibson Dunn represented Arrowhead Pharmaceuticals, Inc. on concurrent public offerings of convertible notes, common stock, and pre-funded warrants to purchase common stock for aggregate gross proceeds of $930 million to Arrowhead and capped call transactions relating to the convertible notes.
Firm News December 3, 2025
Gibson Dunn Represented Mauser Packaging Solutions on $3.9 Billion Notes Exchange, $1 Billion Term Loan Financing, ABL Credit Facility Maturity Extension, and Cash Flow Revolver Maturity Extension
Gibson Dunn represented Mauser Packaging Solutions in an exchange offer of $2.6 billion in aggregate principal amount of their outstanding 7.875% Senior First Lien Notes due 2027 for newly issued 7.875% Senior First Lien Notes due 2030 and $1.3 billion in aggregate principal amount of their outstanding 9.25% Senior Secured Second Lien Notes due 2027 for newly issued 9.25% Senior Secured Second Lien Notes due 2030.
Firm News November 12, 2025
Gibson Dunn Advising Damora Therapeutics on Sale to Galecto and on $285 Million Private Placement by Galecto
Gibson Dunn is advising privately held biotechnology company Damora Therapeutics, Inc. on its sale to Galecto, Inc.
Firm News September 19, 2025
Gibson Dunn Advises 89bio on Its up to $3.5 Billion Sale to Roche Holdings
Gibson Dunn is advising 89bio, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, on its up to $3.5 billion sale to Roche Holdings, Inc.
Client Alert November 10, 2021
Discussing Human Capital: A Survey of the S&P 500’s Compliance with the New SEC Disclosure Requirement One Year After Adoption
A main area of focus for public companies this past annual reporting season was the new human capital disclosure requirement for annual reports on Form 10-K. Gibson Dunn lawyers review disclosure trends among S&P 500 companies and provides practical considerations for companies as we head into 2022 and the second year of discussing human capital resources and management.